2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

2:30PM-4:00PM: Abstract Number: 902

Inhibitor of DNA Binding 1 As a Fibroblast Derived Inflammatory Angiogenic Agonist in Rheumatoid Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

2:30PM-4:00PM: Abstract Number: 904

Intracerebroventricular Tweak (TNF-like weak inducer of apoptosis) Induces Depressive-like Behavior and Cognitive Dysfunction in Non-Autoimmune Mice

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

2:30PM-4:00PM: Abstract Number: 932

IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 939

Long-Term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 938

Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 996

Metabolic Control of Invariant Natural Killer T Cell Function

T cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 935

Microrna-146a Provides Feedback Regulation of Monosodium Urate-Induced Gouty Arthritis in Mice By Targeting Tumor Necrosis Factor Receptor Associated Factor 6 and Interleukin-1 Receptor-Associated Kinase 1

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 931

mTOR Complex 1 Signaling Is Required for the Steady-State in Vivo Development of Inflammatory Monocytes

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 925

Musculoskeletal Ultrasound (MSK-US): Innovation or Overutilization?

Imaging of Rheumatic Diseases I: Ultrasound

2:30PM-4:00PM: Abstract Number: 969

Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy I: Biologics

2:30PM-4:00PM: Abstract Number: 964

Neutrophil Extracellular Traps Are Not Only Targets for ACPA-Positive IgG from Rheumatoid Arthritis Patients but Also Directly Trigger Pro- and Anti-Inflammatory Effects Partly Mediated By the C1q Complement Protein

Rheumatoid Arthritis - Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 940

NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 901

Novel B Cell-Derived Peptide Regulation of Homeostatic T-Cell Trafficking Is Subverted in Rheumatoid Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

2:30PM-4:00PM: Abstract Number: 946

Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis

Muscle Biology, Myositis and Myopathies I

2:30PM-4:00PM: Abstract Number: 1000

Obesity and Foot Problems in the Framingham Foot Study: Does Foot Structure or Foot Function Protect Against Hallux Valgus?

ARHP I: Exemplary Abstracts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].